Lilly expands early access to retatrutide (unapproved obesity drug).
Lilly expands special-access pathway for retatrutide, with clinicians seeking to obtain the unapproved obesity drug for patients.
Montana’s expanded right-to-try framework creates an experimental-access pathway for unapproved CTD treatments like Ceres’ nasal spray, but FDA alignment and timing risks remain.
Montana advances a unique right-to-try framework that lets firms sell unapproved, experimental drugs to paying patients via a private review board, with a $12,500 application fee and clinics potentially starting by year-end, but it faces FDA uncertainty and safety concerns.
Subscribe for real-time topic updates and unlimited access to our intelligence platform.